clinical trial · NCT05129137
Pharmacokinetic Study of a Fixed Dose Combination Nefopam Hydrochloride (30 mg) / Paracetamol (500 mg)
Unither Pharmaceuticals, France·phase1·completed·n = 32
Healthy Volunteersnefopam hydrochloride 30mg X2paracetamol 500 mg X2Combination Product: nefopam hydrochloride 30mg / paracetamol 500mg X2
brief summary
This study aims to assess the pharmacokinetic profile of a Fixed Dose Combination nefopam hydrochloride (30 mg) / paracetamol (500 mg) and individual components taken alone or concomitantly after oral single dose.
started
Nov 29, 2021
primary completion
Dec 27, 2021
completion
Dec 27, 2021
last updated
Oct 31, 2024
official title
Pharmacokinetic Study of a Fixed Dose Combination Nefopam Hydrochloride (30 mg) / Paracetamol (500 mg) and Individual Nefopam Hydrochloride and Paracetamol Taken Alone or Concomitantly After Oral Single Dose
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol